Regulation of DNA‐PK in asthma therapy, anti‐DPK3‐scFv as a novel biological radiosensitizer for cancer therapy, DNA‐PKCS inhibitory agent KU60648 as a promising radiosensitizing mediator for osteosarcoma. Here, PRKDC is linked to osteosarcoma.